1
|
Kosaka Y, Sengoku N, Minatani N, Kikuchi M, Nishimiya H, Waraya M, Enomoto T, Kuranami M, Tanino H, Watanabe M. Abstract P3-09-03: Final result of randomised controlled phase II study of the efficiency of palonosetron, aprepitant, and dexamethasone for day1 with or without dexamethasone on days2 and 3. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-09-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Emesis is one of the major non-hematologic toxicity caused by chemotherapy. The control of Chemotherapy Induced Nausea and Vomiting (CINV) is conducted to a life lengthening. Recently, CINV is controlled by the second generation 5-HT3 receptor blocker (Palonosetron; PALO) and a NK-1 receptor antagonist (Aprepitant; APR). It has been shown that dexamethasone (DEX) with 5-HT3 receptor blocker improves acute / delayed CINV. However, it has not been determined the medication schedule for DEX with PALO and APR. The purpose of this study is evaluated the efficiency of palonosetron, aprepitant and dexamethasone for day1 with or without dexamethasone on days2 and 3. This is final result of current study.
Methods: Breast cancer patients who administered anthracyclin drug regimen have been eligible from April, 2011 to June, 2013. The patients were randomised to group A (PALO/APR/DEX one day) and group B (PALO/APR/DEX three days).
Trial designAprepitant125mg80mg80mg Palonosetron0.75mg dexamethasone9.9mg6.6 mg or placebo6.6 mg or placebo Chemotherapydo days12345
Eighty patients were estimate as study samples. The primary endpoint was a complete response (CR) rate of vomiting, the secondary endpoint was a complete control (CC) rate of vomiting.
Results: Eighty two patients were enrolled in this study. There was not inferiority about CR rate of five days after chemotherapy (81.1% of group A, 82.1% of group B). CC rate of group A (62.2%) was better than that of group B (46.2%). However, CC rate was no significant difference between group A and B. There was no significant difference about any level of nausea between group A and B.
Conclusions: One day of dexamethasone with Palonosetron and Aprepitant treatment is enough to control the emesis of high emetogenic chemotherapeutic agents.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-09-03.
Collapse
Affiliation(s)
- Y Kosaka
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Sengoku
- Kitasato University School of Medicine, Sagamihara, Japan
| | - N Minatani
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kikuchi
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Nishimiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Waraya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Enomoto
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Kuranami
- Kitasato University School of Medicine, Sagamihara, Japan
| | - H Tanino
- Kitasato University School of Medicine, Sagamihara, Japan
| | - M Watanabe
- Kitasato University School of Medicine, Sagamihara, Japan
| |
Collapse
|